Expertise in
14
conditions

Dr. David H. Viskochil

Medical Genetics
81 North Mario Capecchi Drive, 
Salt Lake City, UT 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
14
conditions
81 North Mario Capecchi Drive, 
Salt Lake City, UT 

Overview

David Viskochil is a Medical Genetics provider practicing medicine in Salt Lake City, Utah.

Dr. Viskochil is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Malignant Peripheral Nerve Sheath Tumor, and Prader-Willi Syndrome.

Dr. Viskochil is board certified in American Board Of Medical Genetics & Genomics. He is actively involved in clinical research, co-authoring 99 peer reviewed articles and participating in 10 clinical trials. Dr. Viskochil is currently accepting new patients.

Specialties

Medical Genetics

Licenses

Clinical Genetics in UT

Board Certifications

American Board Of Medical Genetics & Genomics

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

University of Utah Pediatric Genetic & Metabolism Clinic
81 North Mario Capecchi Drive, Salt Lake City, UT 84113
Other Locations
Pediatric Genetics - Dac-shriners
1275 E Fairfax Rd, Salt Lake City, UT 84103

Additional Areas of Focus

Dr. Viskochil has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drug: Mirdametinib
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
Enrollment Status: Completed
Publish Date: May 12, 2026
Intervention Type: Drug
Study Drug: Pitolisant
Study Phase: Phase 2
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: February 17, 2026
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)
Enrollment Status: Completed
Publish Date: May 02, 2025
Intervention Type: Drug
Study Drug: Binimetinib
Study Phase: Phase 2
An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Extended-Release Tablets in Participants With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Extended-Release Tablets in Participants With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
Enrollment Status: Completed
Publish Date: April 19, 2024
Intervention Type: Drug
Study Drug: DCCR (diazoxide choline controlled release tablets)
Study Phase: Phase 3
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome
Enrollment Status: Terminated
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drug: RAD011
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Drug
Study Drug: AGT-181
Study Phase: Phase 1
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)
Enrollment Status: Completed
Publish Date: July 26, 2022
Intervention Type: Drug
Study Drug: Intranasal carbetocin
Study Phase: Phase 3
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

99 Total Publications

Resolution of Refractory Multifocal Atrial Tachycardia in Costello Syndrome Using Trametinib: A Case Supporting MEK Inhibitors as Targeted, Specific Antiarrhythmic.
Resolution of Refractory Multifocal Atrial Tachycardia in Costello Syndrome Using Trametinib: A Case Supporting MEK Inhibitors as Targeted, Specific Antiarrhythmic.
Journal: American journal of medical genetics. Part A
Published: February 09, 2026
Similar Doctors
Expertise in
1
conditions
Dr. Julie R. Korenberg
Medical Genetics
Expertise in
1
conditions
Dr. Julie R. Korenberg
Medical Genetics
Referral required
Before you request

University Of Utah Hospital Neurology Department

50 N Medical Dr, 
Salt Lake City, UT 
 (0.2 miles away)
801-585-6387
Languages Spoken:
English, Filipino, French, German, Spanish
See accepted insurances
Accepting New Patients

Expertise in Downs Syndrome and Williams Syndrome. Dr. Korenberg is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Williams Syndrome. Dr. Korenberg is board certified in American Board Of Medical Genetics , American Board Of Pediatrics, and American Board Of Pediatrics. Dr. Korenberg is currently accepting new patients.

Expertise in
5
conditions
Dr. Douglas J. Ball
Medical Genetics
Expertise in
5
conditions
Dr. Douglas J. Ball
Medical Genetics
Referral may be required

Tanner Memorial Clinic

5296 S Commerce Dr, 
Salt Lake City, UT 
 (8.6 miles away)
801-773-4865
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Douglas Ball is a Medical Genetics provider practicing medicine in Salt Lake City, Utah. Dr. Ball is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Ehlers-Danlos Syndrome (EDS), Brittle Cornea Syndrome, Vascular Ehlers-Danlos Syndrome (VEDS), and Musculocontractural Ehlers-Danlos Syndrome (mcEDS). Dr. Ball is board certified in American Board Of Medical Genetics , American Board Of Preventive Medicine, and American Board Of Preventive Medicine.

Expertise in
12
conditions
Dr. Lorenzo D. Botto
Medical Genetics
Expertise in
12
conditions
Dr. Lorenzo D. Botto
Medical Genetics
Referral may be required

Pediatric Genetics

81 N Mario Capecchi Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-213-3599
Languages Spoken:
English, Italian
See accepted insurances
Accepting New Patients
Offers Telehealth

Lorenzo Botto is a Medical Genetics provider practicing medicine in Salt Lake City, Utah. Dr. Botto is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Omphalocele, Increased Head Circumference, Schwartz-Jampel Syndrome, and X-Linked Spondyloepiphyseal Dysplasia Tarda. Dr. Botto is board certified in American Board Of Pediatrics. Dr. Botto is currently accepting new patients.

Frequently Asked Questions about Dr. David H. Viskochil

How do I make an appointment with Dr. David H. Viskochil?

You can book an appointment with Dr. David H. Viskochil by calling their office at 801-213-3599. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David H. Viskochil a top-rated expert for Neurofibromatosis Type 1 (NF1)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David H. Viskochil is classified as an Elite expert for Neurofibromatosis Type 1 (NF1), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David H. Viskochil specialize in?

While Dr. David H. Viskochil is a Medical Genetics, they have specific expertise in Neurofibromatosis Type 1 (NF1), Neurofibromatosis, and Malignant Peripheral Nerve Sheath Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Medical Genetics.

Does Dr. David H. Viskochil participate in research or clinical trials?

Yes. Dr. David H. Viskochil has published 99 articles and abstracts on conditions like Neurofibromatosis Type 1 (NF1). You can view a list of Dr. David H. Viskochil's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David H. Viskochil accept my insurance?

Dr. David H. Viskochil accepts most major insurance plans, including Aetna and BridgeSpan. We recommend calling the office directly at 801-213-3599 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Viskochil's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile